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Objectives. This study was designed to evaluate whether the
addition of transdermal nitroglycerin or oral N-acetylcysteine, or
both, to conventional medical therapy improves the natural
history of unstable angina pectoris.
Background. Transdermal nitroglycerin is widely used to treat
angina pectoris, but the development of tolerance is a major
problem that may reduce its clinical efficacy. It has been suggested
that the addition of N-acetylcysteine to nitroglycerin reverses the
development of tolerance, potentiates the hemodynamic response
to nitroglycerin and may improve in-hospital prognosis in unsta-
ble angina.
Methods. We assessed the efficacy of adding transdermal
nitroglycerin or oral N-acetylcysteine, or both, to conventional
medical therapy in a randomized, double-blind, placebo-
controlled trial involving 200 patients with unstable angina who
were followed up for 4 months.
Results. Outcome events—death, myocardial infarction or
refractory angina requiring revascularization—occurred in 31%
of patients receiving nitroglycerin, 42% of those receiving
N-acetylcysteine, 13% of those receiving nitroglycerin plus
N-acetylcysteine and 39% of those receiving placebo (p 5 0.0052).
Kaplan-Meier curves showed a higher probability (p < 0.01) of no
failure of medical treatment in the group receiving both nitroglyc-
erin and N-acetylcysteine than in those receiving placebo,
N-acetylcysteine or nitroglycerin alone. The combination of nitro-
glycerin and N-acetylcysteine was associated with a high incidence
of side effects (35%), mainly intolerable headache, which was
almost twice as frequent as in patients receiving nitroglycerin alone.
Conclusions. The combination of nitroglycerin and N-
acetylcysteine, associated with conventional medical therapy in
the long-term treatment of patients with unstable angina, reduces
the occurrence of outcome events. However, the high incidence of
side effects limits the clinical applicability of this therapeutic
strategy at least at the dosage used in the present study.
(J Am Coll Cardiol 1997;29:941–7)
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Although nitroglycerin and other organic nitrates are among
the oldest and most efficacious remedies used to treat anginal
attacks, their clinical efficacy in the long-term management of
angina pectoris is still controversial (1,2). A major problem
with long-term prophylactic nitrate therapy is the development
of tolerance, which may reduce clinical efficacy. The basis for
nitrate tolerance is not completely understood, but the most
widely espoused theory is that continuous nitrate administra-
tion leads to the depletion of the reduced sulfhydryl groups,
which are essential for the pharmacologic effect of nitrates
(3–5).
The sulfhydryl donor N-acetylcysteine has been shown to
enhance nitroglycerin-induced dilation of the smaller coronary
vessels (6), potentiate the hemodynamic response to nitrates
(7–9) and reverse the development of nitrate tolerance (10–
12). In patients with unstable angina receiving intravenous
nitroglycerin, an infusion of high doses of N-acetylcysteine
augmented the efficacy of nitrates and improved short-term
prognosis by preventing the development of acute myocardial
infarction (13). However, it is not known whether long-
term treatment with transdermal nitroglycerin and oral
N-acetylcysteine is effective in improving long-term prognosis
in patients with unstable angina pectoris. This report describes
a 4-month, double-blind, randomized, placebo-controlled trial
designed to examine whether the addition of transdermal
nitroglycerin or oral N-acetylcysteine, or both, to conventional
medical management improves the natural history of unstable
angina pectoris.
Methods
Patient selection. Patients with unstable angina who were
consecutively admitted to our institution and were deemed not
to require emergency coronary revascularization were consid-
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ered eligible to enter the study. A log of all hospital admissions
was kept during the recruitment phase. Unstable angina was
defined as 1) chest pain of recent onset, 2) a sudden worsening
of preexisting stable angina, or 3) postinfarction angina devel-
oping after an asymptomatic period of .12 weeks. The pre-
requisite for inclusion in the study was the occurrence of chest
pain at rest associated with transient ischemic repolarization
changes: that is, the electrocardiographic (ECG) demonstra-
tion of $1-mm ST segment depression or elevation 80 ms after
the J point, T wave inversion or the pseudonormalization of
previously negative T waves. All patients fulfilled the criteria
for class IIB or IIIB of the Braunwald’s classification of
unstable angina.
Patients with the following conditions were excluded from
the study: 1) age .75 years; 2) previous coronary artery bypass
surgery or coronary angioplasty; 3) valvular heart disease; 4)
systolic blood pressure ,100 mm Hg; 5) congenital heart
disease; 6) symptomatic cerebrovascular disease; 7) extracar-
diac conditions that may interfere with 4-month prognosis; and
8) extracardiac conditions that intensify myocardial ischemia,
such as anemia, fever, infections, uncontrolled hypertension,
tachyarrythmias, unusual emotional stress, thyrotoxicosis and
hypoxemia secondary to respiratory failure.
Study protocol. All patients included in the study were
followed up by three cardiologists (G.D., P.Z., A.M.), who
adopted a uniform approach to the management of unstable
angina for investigational purposes. Patients were screened for
the study as soon as the results of coronary arteriography were
available and it was determined that they did not require
emergency coronary revascularization. Emergency coronary
revascularization was performed in patients with left main
coronary artery disease (.50% stenosis) or persistent angina
at rest despite maximal medical therapy. Of a total of 346
screened patients, 146 underwent emergency coronary revas-
cularization, and 200 were considered eligible to enter the
study. After the determination of eligibility, the study protocol
was explained to each patient and their written informed
consent was obtained. The patients were then randomly
assigned on a double-blind basis to one of the following
treatments: 1) nitroglycerin plus N-acetylcysteine placebo; 2)
nitroglycerin placebo plus N-acetylcysteine; 3) nitroglycerin
plus N-acetylcysteine; and 4) nitroglycerin placebo plus
N-acetylcysteine placebo. Throughout the study, the patients
were instructed to record the number and severity of anginal
attacks and their use of nitroglycerin on diary cards, and to
refer to the investigators in charge in the case of any problem.
Ambulatory ECG (Holter) monitoring was used to help the
investigators assess the need for emergency revascularization;
it was performed four times: 1) on the day before randomiza-
tion, 2) on the 1st day of trial drug administration, 3) during
the 2nd week of randomized treatment, and 4) after 4 months.
Follow-up visits, consisting of an ECG and a complete physical
examination, were scheduled 1, 2, 3 and 4 months after
enrollment.
Conventional treatment. On enrollment, patients received
a standardized conventional medical treatment: a combination
of aspirin (300 to 325 mg daily), metoprolol (100 to 200 mg
daily) and nifedipine (40 to 80 mg daily). If aspirin was
contraindicated, it was replaced by ticlopidine (250 to 500 mg
daily); if metoprolol was contraindicated, it was replaced by
diltiazem (180 to 360 mg daily). The protocol required that the
use of these agents be maintained throughout the study period.
Administration of all nitrate medications (except nitroglycerin
to treat anginal attacks) was required to be stopped .4 days
before the start of the study. Other concomitant medications
that were considered necessary for the patients’ welfare and
that did not interfere with the study medications were given at
the discretion of the investigators. The administration of such
drugs had to be recorded in the case report form.
Study drug. The nitroglycerin 10-mg and nitroglycerin
placebo patches were identical, as were the N-acetylcysteine
600-mg and N-acetylcysteine placebo tablets. Because of
the different ways of administering nitroglycerin and
N-acetylcysteine, the double-dummy technique was used. One
nitroglycerin patch (active or placebo) and three N-
acetylcysteine tablets (active or placebo) were given per day.
The trial medications were prepackaged, and four boxes (one
for each month of treatment) of each of the two study drugs
were available. The eight boxes were collected in a patient
medication pack bearing a sequential patient number. To
ensure random allocation to the treatments, each patient was
to be given the patient medication pack bearing the lowest
available patient number. Patient compliance to the trial
treatments was measured by means of residual patch and tablet
counts at each visit. Good compliance was defined as 80% to
120% of scheduled patch or tablet consumption.
Study end points. The primary end point was the 4-month
composite incidence of cardiac death, Q wave and non-Q wave
myocardial infarction, or persistent angina requiring coronary
bypass surgery or angioplasty. In the case of more than one
event, the most serious was counted. Cardiac death was
defined as death due to cardiac causes. Q wave myocardial
infarction was defined as 1) prolonged chest pain; 2) an
increase in creatine kinase levels to more than twice normal
values; 3) the development of new Q waves on the 12-lead
ECG. Non-Q wave myocardial infarction required only the
first two characteristics. Persistent angina requiring coronary
revascularization was defined as the presence of recurrent
anginal chest pain leading to hospital admission. Occasional
angina or angina controlled by medical therapy that did not
require a repeat hospital admission, was not considered an end
point.
Adverse drug reactions were closely monitored at each visit
during the study and were to be recorded on the case report
Abbreviations and Acronyms
CL 5 confidence limits
ECG 5 electrocardiogram, electrocardiographic
OR 5 odds ratio
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form. The following data were to be collected: the nature of
the adverse drug reaction, date of onset and resolution,
severity of the reaction, relation to the trial drug, action taken,
therapy required and outcome. Severe headache was defined
as headache that required analgesic therapy and led to tem-
porary or permanent discontinuation of the study drugs.
Holter monitoring. Continuous two-channel Holter moni-
toring was performed by using Delmar Avionics Electrocardio-
corders (model 445), which have a frequency response of 0.05
to 100 Hz and meet the specifications of the American Heart
Association. The leads showing the most evident ECG changes
during spontaneous anginal attacks were monitored. The leads
with abnormal waves or significant ST segment shifts were
avoided, and control recordings were made in each patient in
the supine, prone, standing and sitting positions. The system
was calibrated before and after each placement. The tapes
were analyzed by a cardiologist (P.Z.) at 60 times real time
under continuous visual inspection, and an episode of transient
ischemia was defined as $1-mm ST segment elevation or
depression occurring 80 ms after the J point, lasting for $1 min
and separated from other episodes by $1 min. When a
significant ST segment change was noted on the monitor, the
episode was recorded on ECG paper at 25 mm/s. The number
and duration of ischemic episodes were recorded.
Coronary arteriography. Selective coronary arteriography
was performed in multiple views by the Sones or Judkins
technique, after premedication with 10 mg of diazepam. Pa-
tients were classified as having one-, two- or three-vessel
disease according to the number of vessels showing significant
coronary stenosis, defined as a .50% narrowing in the diam-
eter of the coronary arteries.
Statistical analysis. The end point status of all of the
patients withdrawn over the 4-month period was established,
and the outcomes were recorded and included in the analysis.
The difference between the four treatment arms was therefore
diluted, because the analysis included patients who had not
received the drug for the entire study period. Although this
type of analysis reduces the probability of demonstrating a
difference between the four arms, we considered this conserva-
tive approach more appropriate than alternative ways of
handling withdrawals.
The results are expressed as odds ratios (OR) and 95%
confidence limits (CL). Event rates were tested by means of
two-tailed chi-square statistics. In addition to performing
contingency table analysis, we considered the time-dependent
nature of treatment failure by applying the Kaplan-Meier
actuarial method to examine failure rates over time. The
Kaplan-Meier actuarial curves were then compared by using a
log-rank test according to the intention to treat principle.
Holter monitoring was performed only in patients actually
receiving the study drug; therefore, the statistical analysis was
performed on a “per protocol” basis. The prevalence of
patients showing at least one ischemic episode at the different
time points was compared within each treatment group by
means of the chi-square test.
Baseline characteristics were compared by using the chi-
square test for discrete variables and the analysis of variance
for continuous variables. All of the presented tests are two-
tailed. A p value ,0.05 was considered statistically significant.
Results
Composition of the study group. A total of 200 patients
were randomized. Protocol deviations were noted in two
patients. In one, the decision to perform emergency coronary
revascularization was taken before administration of the study
medication; the other patient, who was randomized before
giving informed consent, refused to adhere to the protocol.
These patients were followed up for the occurrence of out-
come events and both were analyzed with the others according
to the intention to treat principle. Compliance with the drug
regimen was considered good in 91% of the patients and did
not differ among treatment groups.
The clinical, ECG and angiographic characteristics of the
four study groups are shown in Table 1. No intergroup
differences were observed for any of the baseline variables.
Study end points. The distribution of outcome events is
shown in Table 2. Outcome events occurred in 17 patients
(31%) receiving nitroglycerin, in 19 (42%) receiving
N-acetylcysteine, in 7 (13%) receiving nitroglycerin plus
N-acetylcysteine and in 18 (39%) receiving placebo (p 5
0.0052). The risk of developing an outcome event was signifi-
cantly lower in the group receiving nitroglycerin plus
N-acetylcysteine than in the groups receiving placebo (OR
0.25; 95% CL 0.07, 0.7; p 5 0.0022), nitroglycerin alone (OR
0.31; 95% CL 0.098, 0.90; p 5 0.018) or N-acetylcysteine alone
(OR 0.19; 95% CL 0.06, 0.57; p 5 0.0008). No significant
differences were observed among the groups receiving placebo,
nitroglycerin alone or N-acetylcysteine alone.
Kaplan-Meier curves showing the 4-month probability of
no failure of medical treatment are shown in Figure 1. The
probability of no failure of medical treatment was sig-
nificantly higher in the group receiving nitroglycerin plus
N-acetylcysteine than in each of the other three groups (p ,
0.01). No significant differences were observed among the
groups receiving placebo, nitroglycerin alone or N-
acetylcysteine alone.
Complications. Complications, side effects and their time
of occurrence by treatment group during the 4-month study
period are shown in Tables 3 and 4. Severe headache occurred
in 17 patients receiving nitroglycerin and N-acetylcysteine, an
incidence almost twice that of patients receiving nitroglycerin
alone; it occurred in only 2 patients receiving N-acetylcysteine
alone (1 patient) or placebo (1 patient). Among other compli-
cations, gastrointestinal disorders (epigastralgia and diarrhea)
were the most frequent, occurring mainly in the group receiv-
ing N-acetylcysteine alone. Drug discontinuation because of
side effects was more frequent in the group receiving nitroglyc-
erin plus N-acetylcysteine than in the other treatment groups
(p 5 0.028). Except in the placebo group, most complications
or side effects occurred within the 1st month of treatment.
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Holter monitoring. Table 5 shows the results of Holter
monitoring by treatment group. At baseline, the prevalence of
patients showing the presence of at least one ischemic episode
was similar in the four groups. The prevalence of patients who
had ischemic episodes on Holter monitoring did not differ at
the various time points in the groups receiving placebo,
N-acetylcysteine alone or nitroglycerin alone; in the group
receiving nitroglycerin plus N-acetylcysteine, there was a sig-
nificant reduction in the prevalence of those showing ischemia
on the 1st day of treatment, at the 2nd week and at the 4th
month of treatment (p 5 0.033).
Discussion
Nitrates and the prevention of myocardial ischemia. Ni-
trates relieve or prevent myocardial ischemia by multiple
mechanisms (1). They cause dilation of the venous bed with
peripheral pooling of blood, so that there is a reduced venous
return to the heart with a corresponding reduction in heart
size. They also reduce arterial and arteriolar tone, reductions
that lower systemic pressure and left ventricular volume. The
reduced blood pressure and smaller heart size lead to reduced
myocardial oxygen consumption. In addition, nitrates increase
myocardial oxygen supply by dilating epicardial coronary ar-
teries and enhancing collateral blood flow.
The vasodilating effects of nitrates are currently attributed
(4,5) to stimulation of the production of cyclic guanosine
monophosphate in vascular smooth muscle. It has been sug-
gested (14) that the organic nitrates are converted to nitric
acid, leading to the production of nitric oxide and nitrosothiols
by means of reactions with sulfhydryl-containing compounds.
The nitric oxide and nitrosothiols stimulate guanylate cyclase,
Table 1. Clinical, Electrocardiographic and Angiographic Characteristics of the Study Patients by Treatment Group
Nitroglycerin
(n 5 54)
N-Acetylcysteine
(n 5 45)
Nitroglycerin 1
N-Acetylcysteine
(n 5 55)
Placebo
(n 5 46)
All Patients
(n 5 200)
Clinical
Male 44 (81%) 32 (71%) 45 (82%) 32 (69%) 153 (76%)
Age (yr) 57 6 9 58 6 8 57 6 9 58 6 9 57 6 9
Weight (kg) 73 6 9 70 6 11 72 6 11 74 6 11 72 6 10
Height (cm) 168 6 7 168 6 8 169 6 7 166 6 7 168 6 7
Smoker 25 (46%) 14 (31%) 25 (45%) 13 (28%) 77 (38%)
Diabetes 2 (4%) 4 (9%) 4 (7%) 1 (2%) 11 (6%)
Hypertension 25 (46%) 23 (51%) 22 (40%) 25 (54%) 95 (47%)
Cholesterol (mg/dl) 212 6 30 236 6 38 225 6 40 220 6 28 218 6 36
Prior myocardial infarction 21 (39%) 16 (35%) 14 (25%) 16 (35%) 67 (33%)
Electrocardiographic
ST segment elevation 11 (20%) 10 (22%) 15 (30%) 11 (24%) 47 (23%)
ST segment depression 34 (64%) 28 (63%) 35 (64%) 30 (65%) 127 (63%)
T wave inversion or pseudonormalization 9 (16%) 7 (15%) 5 (9%) 5 (11%) 26 (14%)
Angiographic
Study not performed 5 2 4 5 16
Normal vessels or nonsignificant CAD 4 (8%) 5 (11%) 7 (13%) 0 (0%) 16 (9%)
Vessels with CAD
1 vessel 16 (32%) 9 (20%) 19 (37%) 9 (21%) 53 (29%)
2 vessels 15 (30%) 13 (30%) 17 (33%) 25 (60%) 70 (38%)
3 vessels 13 (26%) 16 (37%) 7 (14%) 7 (17%) 43 (23%)
Left main coronary artery 1 (2%) 0 (0%) 1 (2%) 0 (0%) 2 (1%)
Data presented are number (%) of patients or mean value 6 SD. CAD 5 coronary artery disease.
Table 2. End Point by Treatment Group*
Event
Nitroglycerin
(n 5 54)
N-Acetylcysteine
(n 5 45)
Nitroglycerin 1
N-Acetylcysteine
(n 5 55)
Placebo
(n 5 46)
No. OR 95% CL p Value No. OR 95% CL p Value No. OR 95% CL p Value No.
Death 0 — — — 0 — — — 0 — — — 1
Myocardial infarction 3 1.29 0.14,11.9 0.78 1 0.50 0,7.46 0.57 1 0.41 0,6.05 0.45 2
Persistent angina requiring
revascularization
14 0.72 0.27,1.87 0.46 18 1.38 0.53,3.56 0.46 6 0.25 0.07,0.79 0.0074 15
Any event 17 0.71 0.28,1.76 0.42 19 1.14 0.45,2.86 0.76 7 0.23 0.07,0.67 0.0022 18
*All statistics refer to comparisons with the placebo group. CL 5 confidence limits; No. 5 number of patients; OR 5 odds ratio.
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thus producing the vasodilating cyclic guanosine monophos-
phate. Continued nitrate exposure leads to the depletion of
reduced sulfhydryl groups with a consequent decrease in the
formation of nitric oxide and nitrosothiols, and diminished
activation of guanylate cyclase, which blunts the pharmacologic
effect of nitrates (3).
Effect of N-acetylcysteine. N-acetylcysteine, a source of
sulfhydryl groups, has been shown (10–12) to potentiate the
peripheral and coronary vasodilator effects of nitroglycerin
in vivo, and to prevent the development of tolerance. In
patients with unstable angina, the addition of intravenous
N-acetylcysteine to intravenous nitroglycerin has also been
shown (13) to potentiate the effect of nitrates and improve
short-term, in-hospital prognosis by reducing the occurrence of
myocardial infarction. In this study we evaluated the long-term
clinical effect of adding transdermal nitroglycerin or oral
N-acetylcysteine, or both, to conventional medical treatment in
patients with unstable angina pectoris deemed not to require
emergency coronary revascularization. In comparison with
placebo, no significant differences in outcome were observed
Figure 1. Effect of placebo, nitroglycerin, N-acetylcysteine or combi-
nation therapy with nitroglycerin plus N-acetylcysteine on the cumu-
lative probability of no failure of medical therapy in patients with
unstable angina pectoris. N denotes the number of patients exposed to
the risk at each time point.
Table 3. Complications by Treatment Group
Nitroglycerin
(n 5 54)
N-Acetylcysteine
(n 5 45)
Nitroglycerin 1
N-Acetylcysteine
(n 5 55)
Placebo
(n 5 46)
Severe headache 10 (19%) 1 (2%) 17 (31%) 2 (4%)
Epigastralgia 2 (4%) 5 (11%) 0 0
Diarrhea 0 4 (8%) 1 (2%) 0
Melena 1 (2%) 0 1 (2%) 0
Metrorrhagia 0 0 0 1 (2%)
Epistaxis 0 1 (2%) 0 0
Gingival bleeding 0 0 0 1 (2%)
Anemia 0 1 (2%) 0 0
Renal insufficiency 0 0 0 1 (2%)
Study drug discontinued 12 (22%) 8 (18%) 18 (33%) 4 (8%)
Data are presented as number (%) of patients.
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with the addition of transdermal nitroglycerin or oral
N-acetylcysteine alone, whereas the combination of nitroglyc-
erin and N-acetylcysteine significantly reduced the occurrence
of combined end point events over the 4-month study period.
However, the more pronounced effect of combining nitroglyc-
erin and N-acetylcysteine was associated with a higher inci-
dence of side effects or premature discontinuation, mainly
related to the occurrence of severe headache (thus confirming
the more potent vasodilating effect of the drug combination).
The high incidence of severe headache in those receiving the
drug combination limits the clinical applicability of this thera-
peutic strategy, at least at the doses used in the present study.
Possible mechanisms of beneficial effect of combination
therapy. We performed Holter monitoring only in the patients
who actually received the study medications (thus excluding
those who had already reached an end point or who had
stopped taking the study drug because of side effects). Al-
though our data must be viewed in light of this limitation, it is
interesting that the number of patients showing more than one
ischemic episode was significantly reduced only in the group
treated with nitroglycerin plus N-acetylcysteine. These results
reinforce the finding of a more pronounced effect of the
combination therapy. As we did not observe an early effect that
was lost during follow-up in the group treated with nitroglyc-
Table 4. Timing of Complications by Treatment Group
Nitroglycerin N-Acetylcysteine
Nitroglycerin 1
N-Acetylcysteine Placebo
1st week 3 3 6 1
2nd to 4th week 9 6 10 1
2nd month 0 1 2 1
3rd month 0 1 1 2
4th month 1 1 0 0
Total 13 12 19 5
Data are presented as number of patients.
Table 5. Ambulatory Electrocardiographic Results by Treatment Group
Baseline 1st Day 2nd Week 4th Month p Value
Nitroglycerin (n 5 54)
Ischemic episodes 5 0 43 (81%) 39 (78%) 27 (79%) 23 (88%) 0.731
Ischemic episodes $1 10 (19%) 11 (22%) 7 (21%) 3 (12%)
No. of ischemic episodes
1 7 4 3 1
2 1 4 0 2
3 1 2 0 0
4 0 0 2 0
.5 1 1 2 0
N-acetylcysteine (n 5 45)
Ischemic episodes 5 0 32 (63%) 25 (66%) 21 (78%) 16 (84%) 0.456
Ischemic episodes $1 13 (37%) 13 (34%) 6 (22%) 3 (16%)
No. of ischemic episodes
1 3 7 2 1
2 5 1 2 1
3 3 2 1 1
4 0 2 0 0
.5 2 0 1 0
Nitroglycerin 1 N-acetylcysteine (n 5 55)
Ischemic episodes 5 0 41 (75%) 40 (89%) 27 (90%) 26 (96%) 0.033
Ischemic episodes $1 14 (25%) 5 (11%) 3 (10%) 1 (4%)
No. of ischemic episodes
1 5 0 1 1
2 4 5 1 0
3 1 0 0 0
4 2 0 0 0
.5 1 0 1 0
Placebo (n 5 46)
Ischemic episodes 5 0 35 (76%) 29 (78%) 26 (90%) 17 (85%) 0.473
Ischemic episodes $1 11 (24%) 8 (22%) 3 (10%) 3 (15%)
No. of ischemic episodes
1 4 3 2 2
2 1 2 0 1
3 2 0 1 0
4 4 1 0 0
.5 0 2 0 0
p values compare proportions of patients with ischemic episodes $1 at different time points. Data are presented as
number (%) of patients. 1st day 5 1st 24 h of treatment; 2nd week 5 between the 7th and the 14th day of treatment; 4th
month 5 at the end of the 4th month of treatment.
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erin alone (i.e., the development of tolerance), we cannot
ascribe the beneficial effect of the combination therapy to the
prevention of tolerance.
Another possible explanation for the beneficial effect of the
combination of nitroglycerin and N-acetylcysteine on progno-
sis may be related to the antiplatelet effect of nitroglycerin
(15–17), which is greatly potentiated by N-acetylcysteine at
pharmacologic concentrations achievable in vivo (18–21). In
unstable angina, a condition for which antiplatelet therapy has
been shown (22–25) to improve acute, subacute and long-term
prognosis, this effect may be of particular interest, although its
relevance in patients receiving aspirin, as were those in our
study group, remains to be determined.
Conclusions. The combination of nitroglycerin and
N-acetylcysteine, associated with conventional medical therapy
in the long-term treatment of patients with unstable angina
deemed not to require emergency coronary revascularization,
reduces the occurrence of outcome events. However, the high
incidence of side effects may limit the clinical applicability of
this therapeutic strategy, at least at the doses used in our study.
Further studies are needed to titrate dose regimens at which
the efficacy/tolerability profile may be favorable and clinically
acceptable.
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